Biophytis launches OBA phase 2 clinical study in obesity with BIO101

Biophytis SA announced that it is launching a new clinical development program named OBA, with BIO101 as a potential treatment for obesity in combination with GLP-1 receptor agonists. Obesity treatment can lead to loss of muscle mass and function, notably as a consequence of dieting when combined with the recently introduced GLP-1 receptor agonists. Glucagon-like peptide-1 receptor agonist drugs are very effective drugs that lead to significant weight loss. Up to 40% of the total weight loss comes from muscle, which is a problem as muscle tissue’s role is central in controlling metabolism, on top of its motor function. More than 15 million adults in the US will be treated with an anti-obesity medication by 2030, representing 13% penetration into the US adult population. With an estimated market size of $6 billion in 2023 and an estimated average annual growth rate expected around 42%, the addressable market for the treatment of obesity is set to reach $100 billion by 2030.